Aug 9, 2018
Soligenix BioDefense business segment includes active development programs for RiVax®, its ricin toxin vaccine candidate, OrbeShield®
seen from T1
seen from Venezuela
seen from Latvia
seen from Denmark
seen from United States
seen from United States
seen from Australia
seen from United States
seen from Australia
seen from United States
seen from United States
seen from China
seen from Canada
seen from Austria
seen from United States
seen from United States
seen from Russia
seen from Latvia
seen from Canada
seen from China
Soligenix BioDefense business segment includes active development programs for RiVax®, its ricin toxin vaccine candidate, OrbeShield®
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTC:SNGX) to $4.00
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTC:SNGX) to $4.00
Analyst Ratings For Soligenix (OTC:SNGX) Today, Maxim Group raised its price target on Soligenix (OTC:SNGX) to $4.00 per share. There are 1 buy rating on the stock. The current consensus rating on Soligenix (OTC:SNGX) is Buy (Score: 3.00) with a consensus target price of $4.00 per share, a potential . Some recent analyst ratings include Dividend information for Soligenix (OTC:SNGX) . About…
View On WordPress
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTCBB:SNGX) to $4.00
Analyst Activity – Maxim Group Raises Its Price Target On Soligenix (OTCBB:SNGX) to $4.00
Analyst Ratings For Soligenix (OTCBB:SNGX) Today, Maxim Group raised its price target on Soligenix (OTCBB:SNGX) to $4.00 per share. There are 2 buy ratings on the stock. The current consensus rating on Soligenix (OTCBB:SNGX) is Buy (Score: 3.00) with a consensus target price of $5.00 per share, a potential . Some recent analyst ratings include 9/7/2016-Aegis initiated coverage with a Buy rating.…
View On WordPress